Jeff Aronin heads Marathon Pharmaceuticals, a Northbrook-based prescription drug company that specializes in medications for rare diseases. He is founder and co-chair of health tech incubator Matter and co-chair of ChicagoNext.
Marathon developed a drug that could be the first to treat Duchenne muscular dystrophy, a fatal muscle disease found most often in boys. The drug, Deflazacort, is awaiting FDA approval.
Aronin is also the CEO of Paragon Pharmaceutical Capital, a life sciences investment firm with a portfolio that includes Marathon, SureGene, which develops genetic testing for psychiatric illnesses, and Decade Pharmaceuticals, which develops oncology medications.
Before Marathon, Aronin founded Ovation Pharmaceuticals, which was sold to Danish drugmaker Lundbeck for $900 million. After the acquisition, Aronin served as Lundbeck’s president and CEO.
Aronin is a board member of Discover Financial Services, the Museum of Science and Industry, and the Economic Club of Chicago.
Aronin and his wife, Lisa, have three daughters.
Age: 50 •Websites: marathonpharma.com